Neurobehavioral and neuropsychiatric symptoms in Alzheimer's disease: Characteristics and treatment

Neurologic Clinics

Volumn 18, Issue 4, 2000, Pages 829-846

  Chung, Julia A ^a   Cummings, Jeffrey L ^a,b  

^a Department of Neurology ^*  (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; DONEPEZIL; FLUOXETINE; FLUPHENAZINE; FLUVOXAMINE; GABAPENTIN; HALOPERIDOL; METRIFONATE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SELEGILINE; SERTRALINE; TACRINE; THIORIDAZINE; UNINDEXED DRUG; VALPROIC ACID;

AFFECTIVE NEUROSIS; ALZHEIMER DISEASE; COGNITIVE DEFECT; DISEASE COURSE; DISEASE SEVERITY; HUMAN; INSTITUTIONALIZATION; MENTAL DISEASE; NEUROBIOLOGY; NEUROPSYCHIATRY; PERSONALITY DISORDER; PRIORITY JOURNAL; PSYCHOSIS; RECURRENT DISEASE; REVIEW; SYMPTOMATOLOGY;

EID: 0034523749     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8619(05)70228-0     Document Type: Article

References (92)

1. The course of geriatric depression with "reversible dementia": A controlled study
2. The prevalence, associations and symptoms of depression amongst dementia sufferers
3. Efficacy of antipsychotic medications in behaviorally disturbed dementia patients
4. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease
5. Clinical features and pharmacologic treatment of behavioral symptoms of Alzheimer's disease
6. Aggression, suicide, and serotonin: Relationships to CSF amine metabolites
7. The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia
8. Extrapyramidal side effects in patients with Alzheimer's disease treated with low-dose neuroleptic medication
9. Buspirone vs. haloperidol. A double-blind trial for agitation in a nursing home population with Alzheimer's disease
10. Factors determining the decision to institutionalize dementing individuals: A prospective study
11. Assessment of agitation
12. Agitated behaviors in the elderly: I. A conceptual review
13. Medroxyprogesterone acetate (MPA) treatment of sexual acting out in men suffering from dementia
14. The relationship between dementia and elder abuse
15. Cerebral blood flow correlates of apathy in Alzheimer disease
16. Physostigmine ameliorates the delusions of Alzheimer's disease
17. Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited
18. The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology indementia
19. The course of psychopathologic features in mild to moderate Alzheimer disease
20. A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease
21. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community
22. Clozapine-related seizures
23. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type
24. Prevalence of Alzheimer's disease in a community population of older persons: Higher than previously reported
25. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician
26. Major depression in a population of demented and nondemented older people: Prevalence and correlates
27. Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease
28. Clinical and neuropathological correlates of depression in Alzheimer's disease
29. Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics
30. Propranolol treatment of assaultive patients with organic brain disease. A double-blind crossover, placebo-controlled study
31. Valproic acid treatment of agitation in dementia
32. Frontal lobe hypometabolism and depression in Alzheimer's disease
33. Factors associated with psychotic symptoms in Alzheimer's disease
34. Risperidone treatment of behavioral disturbances in outpatients with dementia
35. The evolution of psychiatric symptoms in Alzheimer's disease: A natural history study
36. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia
37. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial: Risperidone Study Group
38. Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study
39. Pharmacologic approach to management of agitation associated with dementia
40. Efficacy and safety of neuroleptics in behavioral disorders associated with dementia
41. Behavioral effects of trazodone in Alzheimer's disease
42. Effect of carbamazepine on agitation in Alzheimer's inpatients refractory to neuroleptics
43. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease
44. Alzheimer disease and frontotemporal dementias: Behavioral distinctions
45. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior
46. Valproate in the treatment of behavioral agitation in elderly patients with dementia
47. Major and minor depression in Alzheimer's disease: Prevalence and impact
48. Physical aggression in dementia patients and its relationship to depression
49. Noncognitive disturbances in Alzheimer's disease: Frequency, longitudinal course, and relationship to cognitive symptoms
50. Operational criteria for senile dementia of Lewy body type (SDLT)
51. The spectrum of behavioral changes in Alzheimer's disease
52. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
53. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease
54. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: A Nordic multicentre study
55. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia
56. Incontinence and troublesome behaviors predict institutionalization in dementia
57. Assessment of behavioral and affective symptoms in Alzheimer's disease
58. Functional status and cognitive impairment in Alzheimer's patients with and without depression
59. Loxapine in psychogeriatrics: A placebo- and standard-controlled clinical investigation
60. An open trial of valproate for agitation in geriatric neuropsychiatric disorders
61. Efficacy of risperidone for behavioral disorders in the elderly: A clinical observation
62. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients: Metrifonate Study Group
63. Dementia and antipsychotic drugs
64. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease
65. Gabapentin for behavioral agitation in Alzheimer's disease
66. Dementia of the Alzheimer's type and depression
67. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression [see comments]
68. Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment
69. Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease
70. A new rating scale for Alzheimer's disease
71. Depression and Alzheimer's disease
72. Depression and mortality in nursing homes [published erratum appears in JAMA 265:2672, 1991]
73. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: The Alzheimer's Disease Cooperative Study
74. A metaanalysis of controlled trials of neuroleptic treatment in dementia
75. Zolpidem for dementia-related insomnia and nighttime wandering
76. ASPECT study of delusions in Alzheimer's disease
77. Psychiatric symptoms and nursing home placement of patients with Ahheimer's disease
78. Predictors of disease course in patients with probable Alzheimer's disease
79. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia
80. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheirner's disease
81. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Ahheimer's disease
82. Treatment strategies for agitation and psychosis in dementia
83. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia
84. Withdrawal from controlled carbamazepine therapy followed by further carbamazepine treatment in patients with dementia
85. Fluvoxamine for stereotypic behavior in patients with dementia
86. Treatment of depression in advanced Alzheimer's disease using sertraline
87. Psychogeriatric dependency rating scales (PGDRS): A method of assessment for use by nurses
88. Major depression in primary dementia: Clinical and neuropathologic correlates
89. Neurochemical correlates of major depression in primary dementia
90. Neuropathologic and neurochemical correlates of psychosis in primary dementia
91. The neuropathology of aminergic nuclei in Ahheimer's disease